Merel A. van der Most
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Merel A. van der Most has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Nico W. van Den Brink
Department of Toxicology, Wageningen University, Wageningen, The Netherlands
2 shared publications Ignacio Miro Estruch
Division of Toxicology, Wageningen University and Research, Wageningen 6708 WE, The Netherlands
1 shared publication- Ivonne M. C. M. Rietjens
Division of Toxicology, Wageningen University, Stippeneng 4, 6708 WE Wageningen, The Netherlands
1 shared publication Nico W. van Den Brink
Division of Toxicology, Wageningen University and Research, Wageningen 6708 WE, The Netherlands
1 shared publicationSebastiaan Wesseling
Division of Toxicology, Wageningen University and Research, Wageningen 6708 WE, The Netherlands
1 shared publication- Wouter Bakker
Division of Toxicology, Wageningen University & Research, Wageningen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 9 July 2024
- Published by Elsevier in Chemosphere
- Vol. 363, 142819
Evaluating non-monotonic dose-response relationships in ecotoxicological risk assessment: A case study based on a systematic review of data on fluoxetine
- 9 July 2024
- Published by Elsevier in Chemosphere
- Vol. 363, 142819
Open AccessEvaluating non-monotonic dose-response relationships in ecotoxicological risk assessment: A case study based on a systematic review of data on fluoxetine
- Open Access
- 11 February 2024
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 58 (7) , 3129-3140
Toxicokinetics of the Antidepressant Fluoxetine and Its Active Metabolite Norfluoxetine in Caenorhabditis elegans and Their Comparative Potency
The nematode Caenorhabditis elegans is a valuable model for ecotoxicological research, yet limited attention has been given to understanding how it absorbs, distributes, metabolizes, and excretes chemicals. This is crucial for C. elegans because the organism is known to have strong uptake barriers that are known to be susceptible to potential confounding effects of the presence of Escherichia coli as a food source. One frequently studied compound in C. elegans is the antidepressant fluoxetine, which has an active metabolite norfluoxetine. In this study, we evaluated the toxicokinetics and relative potency of norfluoxetine and fluoxetine in chemotaxis and activity tests. Toxicokinetics experiments were conducted with varying times, concentrations of fluoxetine, and in the absence or presence of E. coli, simulated with a one-compartment model. Our findings demonstrate that C. elegans can take up fluoxetine and convert it into norfluoxetine. Norfluoxetine proved slightly more potent and had a longer elimination half-life. The bioconcentration factor, uptake, and elimination rate constants depended on exposure levels, duration, and the presence of E. coli in the exposure medium. These findings expand our understanding of toxicokinetic modeling in C. elegans for different exposure scenarios, underlining the importance of considering norfluoxetine formation in exposure and bioactivity assessments of fluoxetine.
- 11 February 2024
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 58 (7) , 3129-3140
Open AccessToxicokinetics of the Antidepressant Fluoxetine and Its Active Metabolite Norfluoxetine in Caenorhabditis elegans and Their Comparative Potency
The nematode Caenorhabditis elegans is a valuable model for ecotoxicological research, yet limited attention has been given to understanding how it absorbs, distributes, metabolizes, and excretes chemicals. This is crucial for C. elegans because the organism is known to have strong uptake barriers that are known to be susceptible to potential confounding effects of the presence of Escherichia coli as a food source. One frequently studied compound in C. elegans is the antidepressant fluoxetine, which has an active metabolite norfluoxetine. In this study, we evaluated the toxicokinetics and relative potency of norfluoxetine and fluoxetine in chemotaxis and activity tests. Toxicokinetics experiments were conducted with varying times, concentrations of fluoxetine, and in the absence or presence of E. coli, simulated with a one-compartment model. Our findings demonstrate that C. elegans can take up fluoxetine and convert it into norfluoxetine. Norfluoxetine proved slightly more potent and had a longer elimination half-life. The bioconcentration factor, uptake, and elimination rate constants depended on exposure levels, duration, and the presence of E. coli in the exposure medium. These findings expand our understanding of toxicokinetic modeling in C. elegans for different exposure scenarios, underlining the importance of considering norfluoxetine formation in exposure and bioactivity assessments of fluoxetine.
- Open Access
- 5 January 2023
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 250, 114493
Contrasting dose response relationships of neuroactive antidepressants on the behavior of C. elegans
- 5 January 2023
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 250, 114493
Open AccessContrasting dose response relationships of neuroactive antidepressants on the behavior of C. elegans